Evidence map›Paper›PMID 22993654›Full record

ArticleInternational journal of clinical and experimental medicine2012

Estrogen receptor genes variations and breast cancer risk in Iran.

Sakineh Abbasi, Mehrnaz Nouri, Cyrus Azimi

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sakineh AbbasiDepartment of Medical Biotechnology, School of Allied Medical Sciences, Tehran University of Medical Sciences Iran. sakineh4612004@yahoo.com
Mehrnaz Nouri
Cyrus Azimi
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor α (ER-α) and estrogen receptor β (ER-β) occur during breast cancer development. ER-α and ER-β genes polymorphisms have been found to be associated with breast cancer and clinical features of the disease in the western countries. In the current study, we evaluated the hypothesis that certain sequence variants of the ER-α and ER-β genes are associated with an additively increased risk for breast cancer in Iranian women breast cancer patients. The genes were scanned in 150 Iranian patients with newly diagnosed invasive breast tumors and in healthy control individuals by PCR single-strand conformation polymorphism (SSCP) method. Three single nucleotide polymorphisms (SNPs) in codon10 (TCT→TCC), codon 352 (CCG→CCC) and codon 594 (ACG→ACA) in ER-α gene and one SNP codon 392 (CTC→CTG) in ER-β were revealed have additive effects in developing breast cancer and LN metastases. Also, SNP in codon 392 of estrogen receptor-β gene is more effective (threefold) than those SNPs in codons 10, 325, 594 of estrogen receptor-α gene in developing LN metastases in breast cancer patients. SNPs in estrogen receptor α and β have additive effects in increasing risk for developing breast cancer with LN metastases among Iranian women breast cancer patients.

Indexed as

Breast cancerestrogen receptorLN metastasespolymorphism

Identifiers

PMID22993654
PMCPMC3443893
OpenAlexW1732509348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.